Countries with the Highest Cancer Rates (2025 Ranked)

Australia tops every global cancer incidence league table, yet its cancer survival outcomes rank among the world's best. That paradox is the key to reading this data correctly. The countries with the highest reported cancer rates are not the most unhealthy — they are, in most cases, the most diagnostically thorough. Understanding what cancer rankings actually measure is more useful than the headline numbers alone.

Source: IARC Global Cancer Observatory — GLOBOCAN 2022 database, covering 185 countries and 36 cancer types. Figures are age-standardised to allow comparison across populations with different age structures.

What This Ranking Actually Measures

Incidence — the number of newly diagnosed cancer cases per 100,000 people per year, age-standardised — is what most international rankings report. It is not a measure of how many people "have" cancer at any given moment, nor is it a direct measure of cancer deaths.

Two countries can have identical underlying cancer risk but very different reported incidence rates. The country with universal mammography screening will find breast cancers that the country without screening simply never diagnoses. Those undetected cancers still kill people — but they show up in the mortality column attributed to "unknown causes" rather than in the cancer incidence column.

Mortality — the number of deaths attributed to cancer per 100,000 people — is a harder number to fake with detection gaps. Comparing incidence and mortality side by side reveals which countries detect cancers they then go on to survive (high incidence, low mortality) versus which countries have genuine cancer prevention advantages versus which countries simply miss diagnoses (low incidence, high mortality relative to incidence).

Age-standardisation adjusts for the age structure of each country's population. Older populations will always have more cancer, because most cancer risk increases with age. The standardisation allows comparison of the underlying risk, not just the raw count.

Methodology: How GLOBOCAN Builds These Estimates

The IARC's GLOBOCAN database does not simply collect national statistics. It uses a modelling framework because cancer registry coverage varies dramatically by country.

In high-income countries with national cancer registries (Australia, Denmark, United States, UK), GLOBOCAN uses actual registry data covering close to 100% of the population. In middle-income countries, GLOBOCAN typically uses data from regional registries covering a subset of the population, then extrapolates. In low-income countries with minimal registry infrastructure, GLOBOCAN uses mortality statistics, hospital records, and modelled estimates based on comparable countries.

The practical implication: high-income countries' figures are accurate. Low-income countries' figures are estimates that systematically underestimate true incidence, because cases that never reach a hospital never get registered.

Source: IARC — "Global Cancer Observatory: Cancer Today" — gco.iarc.fr, 2022 data release. The database notes that population-based cancer registry coverage is "high" in Europe and North America, "medium" in Latin America and East Asia, and "low" in most of sub-Saharan Africa.

Countries by Age-Standardised Cancer Incidence

New cases per 100,000 people, age-standardised, GLOBOCAN 2022.

Rank	Country	Incidence (per 100K)	Mortality (per 100K)	Survival Signal
1	Australia	468	101	Very good survival (low mortality/incidence ratio)
2	New Zealand	438	106	Similar to Australia
3	Ireland	374	108	Good survival
4	Hungary	368	168	High mortality — treatment access gaps
5	United States	362	93	Best survival outcomes globally
6	Belgium	361	109	Good survival
7	France	352	102	Good survival
8	Denmark	351	103	Good survival
9	Canada	348	93	Among best survival globally
10	Norway	340	95	Strong screening programmes
11	Netherlands	340	102	Good survival
12	Germany	332	106	Good survival
13	United Kingdom	324	100	Good survival
14	Sweden	320	96	Strong outcomes
15	Czech Republic	320	127	Elevated mortality signals treatment gaps
~20	Japan	285	91	Excellent survival; stomach cancer cluster
~30	Brazil	213	101	Under-detection issue
~50	India	104	71	Significant under-detection
~60	Nigeria	89	62	Very high under-detection

Notice the outliers. Hungary sits fourth in incidence but has mortality of 168 per 100,000 — the highest mortality-to-incidence ratio among high-income countries. This reflects real treatment access gaps in the Hungarian healthcare system. Meanwhile, Nigeria has a low-looking incidence rate of 89, but its mortality of 62 implies that a very high proportion of detected cancers result in death — consistent with late-stage diagnosis and limited treatment.

Source: IARC Global Cancer Observatory (GLOBOCAN 2022); National cancer registries; WHO cancer mortality databases.

Where this data comes from

Cancer incidence figures come from the International Agency for Research on Cancer's GLOBOCAN database, which compiles data from national cancer registries, mortality records, and survey data across 185 countries. High-income countries (Australia, Denmark, US, UK) have comprehensive cancer registries covering near-100% of their populations, making those figures highly reliable. Middle-income countries have registries covering major cities and regions but not rural areas. Low-income countries have minimal registry infrastructure, so incidence figures are modelled using hospital records, mortality statistics, and indirect estimation based on risk factor prevalence. This systematic bias means low-income countries' incidence figures are underestimates — sometimes severe ones — because many cancers never reach a hospital and are therefore not registered. Mortality data is more universally available through death certificates, but quality varies by country's vital registration system.

What cancer rankings reveal about healthcare systems

The incidence rankings alone tell a simple story (wealthy countries have more cancer); the incidence-mortality comparison reveals the true story (wealthy countries detect cancer earlier and treat it better, while lower-income countries have both higher true incidence and higher case fatality rates). Australia's first-place position driven by melanoma screening is genuinely protective; the UK and US high incidence with low mortality reflects breast, colorectal, and prostate screening catching cancers at survivable stages. Hungary's high incidence but dramatically elevated mortality reveals healthcare gaps despite national registry data. Nigeria's low-looking incidence obscures a true disaster: a population with high cancer burden that mostly goes undiagnosed and untreated. The real story of global cancer is that incidence tells you about detection infrastructure and screening programmes, while mortality tells you about access to treatment. Both are important; neither alone is sufficient.

Why Australia Leads in Cancer Incidence

Australia's position at the top of this table is driven by three converging factors that have nothing to do with being unusually unhealthy.

Melanoma and UV exposure. Australia has the world's highest melanoma incidence rate — approximately 36 per 100,000 for melanoma alone, versus roughly 4 per 100,000 in the UK. A predominantly fair-skinned population of European descent lives under some of the world's most intense ultraviolet radiation. The ozone layer over Antarctica creates a UV hotspot that particularly affects southern states. Australia's "Slip, Slop, Slap" sun-safety campaign, launched by Cancer Council Australia in 1981, became one of public health's most studied behaviour-change programmes. Melanoma rates have nonetheless remained very high, because the cumulative UV damage that causes melanoma accumulates over decades, meaning today's incidence reflects exposure from the 1970s and 1980s.

Source: Cancer Council Australia — "Skin Cancer Statistics" — cancer.org.au. Australia and New Zealand have the highest melanoma incidence rates in the world.

Comprehensive screening programmes. Australia runs three national cancer screening programmes: the National Bowel Cancer Screening Programme (faecal immunochemical testing offered every two years from age 45), BreastScreen Australia (free mammograms every two years from age 40–74), and the National Cervical Screening Programme (which switched from cytology Pap smears to the more sensitive HPV test in 2017). High uptake of these programmes detects cancers that in less thoroughly screened populations would remain undiagnosed until they caused symptoms — typically at a more advanced stage.

The detection paradox. Despite the world's highest incidence rate, Australia has very good cancer survival outcomes. The five-year relative survival rate for all cancers combined in Australia is approximately 70%, among the highest globally. This is the detection paradox made concrete: finding more cancers, particularly at early stages, raises the incidence number while simultaneously lowering the mortality number.

Source: Australian Institute of Health and Welfare — "Cancer in Australia 2024" — aihw.gov.au.

A Historical Look: How Cancer Rankings Have Shifted Since 1990

Cancer incidence and mortality patterns have shifted significantly over the past three decades, and the direction of change depends heavily on which cancer type and which country you examine.

In high-income countries, the story of the past 30 years is largely one of lung cancer decline and other cancer rises. Smoking rates in the US, UK, and Australia peaked in the 1960s–1970s. Lung cancer incidence in men began declining in these countries in the 1980s and 1990s as the smoking cohort aged and shrank. US male lung cancer incidence has declined by approximately 40% since its peak. This is one of public health's genuine achievements.

Against that, colorectal cancer, obesity-associated cancers (endometrial, kidney, liver, pancreatic, and some breast cancers), and skin cancer have risen in high-income countries. Obesity has overtaken smoking as the leading modifiable cancer risk factor for several cancer types in countries where smoking prevalence has fallen substantially.

In middle-income countries, particularly China, the transition has gone in the opposite direction. Rapid urbanisation, adoption of processed food diets, rising smoking rates (particularly among men), and increasing air pollution exposure have driven substantial increases in lung, colorectal, and breast cancer rates since 1990. China's lung cancer incidence rate increased by more than 40% between 1990 and 2019, according to GBD estimates.

In sub-Saharan Africa, infection-related cancers — cervical cancer from HPV, liver cancer from hepatitis B and C, stomach cancer from H. pylori — remain a much higher proportion of the cancer burden than in wealthy countries. This is slowly changing as hepatitis B vaccination programmes mature, but the change is measured in decades, not years.

Source: Global Burden of Disease Cancer Collaboration — "Global Cancer Incidence and Mortality Rates and Trends" — JAMA Oncology, 2022 update.

Why This Ranking Matters Beyond the Numbers

The incidence ranking matters for three reasons that go beyond academic interest in which country sits at the top of a table.

First, it exposes a global detection gap that kills people. The low incidence numbers in Nigeria, Ethiopia, and Bangladesh are not evidence that people there get cancer at lower rates. They are evidence of systematic under-diagnosis. Millions of people die of cancer without a diagnosis, without treatment, without being counted. When international health funders use low incidence numbers to justify not investing in cancer care in low-income countries, they are misreading data to argue against addressing a real problem.

Second, it illustrates that screening is a double-edged tool. Increased screening raises incidence rates while potentially not changing mortality rates if treatments do not work, or while lowering mortality rates if early detection enables curative treatment. Prostate cancer screening using PSA (prostate-specific antigen) tests has been highly controversial precisely because PSA screening detects many slow-growing prostate cancers that would never become life-threatening, creating a population of "patients" who undergo surgery and radiation with no survival benefit. Distinguishing beneficial over-detection from harmful over-treatment requires careful population-level study.

Third, it drives resource allocation. Countries and insurers use incidence data to decide which screening programmes to fund, which drugs to prioritise, and where to invest prevention resources. Accurate data, and accurate interpretation of that data, literally determines which cancers get treated and which do not. Tobacco use is one major risk factor, covered in countries with the highest smoking rates.

Deep Dive: The United States — High Incidence, Best Survival

The United States ranks 5th in cancer incidence globally, but by most measures has the world's best cancer survival outcomes. Understanding why explains much about how wealth, healthcare organisation, and research investment interact with cancer outcomes.

Five-year survival rates. US cancer survival rates are consistently among the highest globally. Breast cancer five-year survival in the US is approximately 91%, compared to 70–75% in many European countries and lower still in low-income countries. Colorectal cancer five-year survival in the US is approximately 65%, compared to a global average of around 42%. The difference is not primarily about the biology of American cancers — it reflects earlier-stage detection through screening, and faster access to the newest treatments.

Source: Surveillance, Epidemiology, and End Results Program (SEER) — seer.cancer.gov, 2023 data. SEER tracks approximately 48% of the US population across population-based registries.

The obesity burden. Approximately 40% of US cancers are attributable to modifiable risk factors. The American Cancer Society estimates that excess body weight, physical inactivity, alcohol consumption, and poor nutrition together account for 18% of all cancer cases and 16% of cancer deaths in the US. This share is rising as obesity rates increase. Obesity is now the leading modifiable cause of cancer in non-smoking Americans — overtaking alcohol in several cancer types including endometrial, kidney, and liver cancer.

Racial and socioeconomic disparities. US cancer survival statistics obscure enormous within-country inequalities. Black Americans have higher cancer incidence and higher cancer mortality than white Americans for most cancer types. Black men have the highest prostate cancer mortality rate in the world — a rate approximately twice that of white American men, driven by later-stage diagnosis rather than differential tumour biology in most cases. American Indian and Alaska Native populations have the highest overall cancer mortality rates of any US racial group. These disparities are attributable to differential screening rates, insurance coverage gaps, later-stage diagnosis at presentation, and unequal access to the newest therapies.

The immunotherapy revolution. US research institutions — Memorial Sloan Kettering, MD Anderson, Dana-Farber, the NIH's National Cancer Institute — led the development of immune checkpoint inhibitor therapy, one of oncology's most significant advances since chemotherapy. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo), which release the brakes on the immune system to attack cancer cells, have transformed five-year survival for melanoma (previously ~15%, now over 50% for some patient groups), non-small-cell lung cancer, and several other cancer types. These therapies were developed and initially deployed in the US and reached US patients years before many other countries.

Source: Larkin J, et al. — "Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma" — New England Journal of Medicine, 2019. DOI: 10.1056/NEJMoa1910836.

Deep Dive: Hungary — The Warning in the Data

Hungary presents the starkest contrast in the top 15. Its incidence rate of 368 per 100,000 is high but not dramatically higher than Ireland or Belgium. Its mortality rate of 168 per 100,000 is by far the highest in the European Union, and one of the highest globally among high-income countries.

The implied case fatality ratio — the proportion of detected cancer cases that result in death — tells a story of healthcare system failure even in the context of cancer detection. Hungary has functioning cancer registries, so the incidence figure is reasonably reliable. The high mortality reflects late-stage diagnosis (so screening programmes have not been effective enough), limited access to the newest therapies, and healthcare quality gaps compared to Western Europe.

Colorectal cancer and lung cancer are the primary drivers of Hungary's elevated mortality. Hungary has among Europe's highest smoking rates and high alcohol consumption rates. It also has lower uptake of colorectal screening than Western European neighbours.

Source: ECIS — European Cancer Information System — ecis.jrc.ec.europa.eu, 2022 estimates. Hungary's colorectal cancer mortality rate is the highest in the European Union.

Low-Income Countries: The Hidden Burden

The low cancer incidence numbers in low-income countries are misleading. They reflect missed diagnoses, not lower cancer risk.

The diagnostic gap. A study in The Lancet Oncology estimated that nearly 7 million cancer cases go undiagnosed globally each year, concentrated in sub-Saharan Africa and South Asia. People in these regions die of cancer — the cancer just gets attributed to pain, weight loss, or organ failure without a diagnostic workup. The true cancer incidence in countries like Nigeria and Ethiopia is almost certainly several times the GLOBOCAN reported figure.

Source: Bray F, et al. — "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" — CA: A Cancer Journal for Clinicians, 2024. DOI: 10.3322/caac.21834.

Infection-related cancers. In low-income countries, a substantially higher proportion of cancers have infectious causes — which means they are preventable with vaccines and treatments that already exist.

Cervical cancer (caused by persistent HPV infection) is the clearest example. Low-income countries account for 85% of cervical cancer cases and deaths globally. In high-income countries with widespread HPV vaccination and screening, cervical cancer has become rare. The HPV vaccine (Gardasil-9) prevents infection by the nine HPV strains responsible for approximately 90% of cervical cancers. Countries that have achieved high HPV vaccination coverage have already seen cervical cancer rates begin to decline among vaccinated cohorts. The barrier to global cervical cancer elimination is not scientific — it is distribution logistics and pricing.

Source: WHO — "Human papillomavirus vaccines: WHO position paper" — Weekly Epidemiological Record, 2022.

Liver cancer from chronic hepatitis B infection follows the same pattern. Countries with high hepatitis B vaccination coverage have seen liver cancer rates fall among vaccinated birth cohorts. Taiwan, which introduced universal neonatal hepatitis B vaccination in 1984, has documented dramatic reductions in liver cancer among people born after the vaccination programme began.

Source: Chang MH, et al. — "Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children" — New England Journal of Medicine, 1997. DOI: 10.1056/NEJM199706263362602. (This long-running study remains a landmark in preventive oncology.)

Trends to Watch: What Changes in the Next Decade

Obesity-driven cancers will keep rising. With global obesity rates continuing to increase — the WHO estimates that over 1 billion people were living with obesity in 2022 — the obesity-attributable cancers (endometrial, kidney, liver, postmenopausal breast, colorectal, pancreatic, esophageal) will increase accordingly, particularly in countries where smoking reduction has been achieved but dietary transition has not. For the evidence on reducing risk, see what science says about cancer prevention.

Source: WHO — "Obesity and overweight" fact sheet — who.int, 2024 update.

Liquid biopsies may transform early detection. Multi-cancer early detection (MCED) blood tests — which detect fragments of tumour DNA in the bloodstream — are moving through clinical trial and early deployment phases. GRAIL's Galleri test, which can detect more than 50 cancer types from a single blood draw, received Breakthrough Device designation from the FDA. If MCED tests achieve sufficient sensitivity and specificity and are deployed at population scale, they could dramatically increase incidence numbers (by detecting cancers missed by current organ-specific screening) while reducing mortality (by catching them earlier). The net effect on how countries rank may be significant.

Lung cancer treatment is improving faster than any other. Advances in targeted therapy and immunotherapy have transformed lung cancer from almost universally fatal to manageable in a growing subset of patients. Patients with EGFR mutations, ALK rearrangements, and high PD-L1 expression now have treatment options that were unavailable a decade ago. Five-year survival for non-small-cell lung cancer diagnosed at an early stage now exceeds 60% in countries with access to the newest targeted therapies.

AI-assisted imaging diagnostics. AI systems for reading mammograms, CT colonography, and chest X-rays are being deployed in several countries. A 2023 randomised trial in Sweden found that AI-supported mammography screening detected 20% more cancers than radiologist-only reading, with similar false-positive rates. If AI imaging tools are validated at scale and deployed broadly, detection rates — and thus incidence figures — will increase further.

Source: Lång K, et al. — "Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI)" — The Lancet Oncology, 2023. DOI: 10.1016/S1470-2045(23)00298-X.

Frequently Asked Questions

Q: What are the most common cancers globally? A: By incidence: breast cancer (2.3 million new cases per year), lung cancer (2.2M), colorectal cancer (1.9M), prostate cancer (1.4M), stomach cancer (1.1M). By mortality: lung cancer (1.8M deaths), colorectal (935K), liver (830K), stomach (769K), breast (685K). Lung cancer's exceptional lethality relative to its incidence reflects that most cases are diagnosed at an advanced, non-resectable stage — the opposite of breast cancer, where screening and self-examination drive earlier detection.

Source: GLOBOCAN 2022 — IARC Global Cancer Observatory.

Q: Is the global cancer burden increasing or decreasing? A: Total cancer cases are increasing, primarily because of population growth and ageing — cancer risk rises with age, and the global population is growing older. Age-standardised incidence rates (which adjust for this demographic shift) show more modest increases in high-income countries and meaningful increases in many middle-income countries as lifestyles change. Lung cancer rates are declining in countries where smoking has fallen substantially. Age-standardised cancer mortality rates have fallen in high-income countries over the past 20 years, driven by better treatment. Whether the underlying cancer risk is rising or falling depends entirely on which country and cancer type you examine.

Q: What is the most preventable cancer? A: Lung cancer is the most preventable by absolute numbers — approximately 85% of lung cancer cases are attributable to tobacco smoking. Other highly preventable cancers: liver cancer (hepatitis B vaccination and alcohol reduction), cervical cancer (HPV vaccination and screening), colorectal cancer (screening and diet), and skin cancer (UV protection). Collectively, public health modelling suggests 40–50% of all cancers are preventable with interventions that already exist and are cost-effective.

Q: Why does Japan have relatively low mortality despite moderate incidence? A: Japan's cancer survival outcomes are among the world's best, particularly for gastrointestinal cancers. Japan has a stomach cancer cluster — H. pylori infection rates were historically very high — but has invested heavily in early detection through upper endoscopy screening, catching gastric cancers at resectable stages. Japan has now also launched mass H. pylori eradication programmes that are reducing the underlying stomach cancer risk. For other cancer types, Japan's survival rates are comparable to Western Europe.

Q: How much does cancer treatment cost, and does cost affect outcomes? A: Enormously, and yes. In the US, a course of pembrolizumab immunotherapy for lung cancer costs approximately $150,000–$200,000 per year before insurance adjustments. CAR-T cell therapies for certain blood cancers have list prices of $400,000–$500,000 per treatment. High-income countries with universal healthcare systems (UK NHS, Canada, Australia) negotiate prices and cover most modern cancer drugs, though with delays compared to the US. Middle-income countries increasingly have access to generic versions of older drugs, but targeted therapies and immunotherapies are often inaccessible. The gap in survival outcomes between the US and sub-Saharan Africa reflects cost and access at least as much as it reflects detection differences.

Q: Is childhood cancer increasing? A: Yes, modestly, in most high-income countries. Childhood cancer incidence has increased by approximately 1% per year in the US over the past 40 years, according to SEER data. The causes are not well understood. Survival from childhood cancer has improved dramatically — overall five-year survival from childhood cancer in the US exceeds 85%, up from approximately 60% in the 1970s. Acute lymphoblastic leukaemia, the most common childhood cancer, now has a cure rate above 90% in high-income countries.

The Takeaway

Countries with the highest reported cancer rates — Australia, Denmark, the US — are not the world's most unhealthy. They are the world's most diagnostically thorough, combined with specific environmental exposures (Australian UV) and dietary and lifestyle risks. The low cancer incidence numbers in Nigeria, India, and much of sub-Saharan Africa are a measurement artifact, not evidence of cancer-protective advantage. The real global cancer divide is not between high-incidence and low-incidence countries — it is between countries that detect cancer early and treat it effectively and countries where cancer is diagnosed late or not at all. Closing that gap requires HPV and hepatitis B vaccination, basic diagnostic capacity, and access to treatments that have existed for decades but remain unavailable across large parts of the world.

---

Read next:

• Countries with the Highest Life Expectancy
• Countries with the Best Healthcare Systems
• Countries with the Highest Obesity Rates
• Countries with the Most Doctors Per Capita
• Countries with the Most Diabetes